JP2022530192A5 - - Google Patents

Info

Publication number
JP2022530192A5
JP2022530192A5 JP2021560095A JP2021560095A JP2022530192A5 JP 2022530192 A5 JP2022530192 A5 JP 2022530192A5 JP 2021560095 A JP2021560095 A JP 2021560095A JP 2021560095 A JP2021560095 A JP 2021560095A JP 2022530192 A5 JP2022530192 A5 JP 2022530192A5
Authority
JP
Japan
Prior art keywords
plasmid
helper
gene
functional
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530192A (ja
JP7562558B2 (ja
Filing date
Publication date
Priority claimed from GBGB1905263.8A external-priority patent/GB201905263D0/en
Priority claimed from EP19169121.1A external-priority patent/EP3722434B1/en
Application filed filed Critical
Priority claimed from PCT/GB2020/050947 external-priority patent/WO2020208379A1/en
Publication of JP2022530192A publication Critical patent/JP2022530192A/ja
Publication of JP2022530192A5 publication Critical patent/JP2022530192A5/ja
Application granted granted Critical
Publication of JP7562558B2 publication Critical patent/JP7562558B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560095A 2019-04-12 2020-04-14 プラスミドシステム Active JP7562558B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1905263.8A GB201905263D0 (en) 2019-04-12 2019-04-12 Plasmid system
GB1905263.8 2019-04-12
EP19169121.1 2019-04-12
EP19169121.1A EP3722434B1 (en) 2019-04-12 2019-04-12 Plasmid system
PCT/GB2020/050947 WO2020208379A1 (en) 2019-04-12 2020-04-14 Plasmid system

Publications (3)

Publication Number Publication Date
JP2022530192A JP2022530192A (ja) 2022-06-28
JP2022530192A5 true JP2022530192A5 (enExample) 2023-04-17
JP7562558B2 JP7562558B2 (ja) 2024-10-07

Family

ID=70295566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560095A Active JP7562558B2 (ja) 2019-04-12 2020-04-14 プラスミドシステム

Country Status (11)

Country Link
US (2) US20220162642A1 (enExample)
EP (1) EP3953482A1 (enExample)
JP (1) JP7562558B2 (enExample)
KR (1) KR20220019669A (enExample)
CN (1) CN113891942A (enExample)
AU (1) AU2020272557A1 (enExample)
BR (1) BR112021020401A2 (enExample)
CA (1) CA3136545A1 (enExample)
IL (2) IL296544A (enExample)
SG (1) SG11202111149VA (enExample)
WO (1) WO2020208379A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
DK3722434T3 (da) 2019-04-12 2022-10-24 Freeline Therapeutics Ltd Plasmidsystem
CN114929735A (zh) 2019-11-01 2022-08-19 自由行疗法有限公司 因子viii构建体
JP2024504365A (ja) * 2021-01-22 2024-01-31 バイオジェン・エムエイ・インコーポレイテッド 組換えウイルスベクター力価を増加させる微小管不安定化剤添加剤
BR112023016997A2 (pt) * 2021-02-26 2023-11-07 Logicbio Therapeutics Inc Fabricação e uso de vetores aav recombinantes
EP4410971A4 (en) * 2021-09-30 2025-06-04 FUJIFILM Corporation METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR
GB202214328D0 (en) 2022-09-29 2022-11-16 Freeline Therapeutics Ltd Method
WO2024160232A1 (zh) * 2023-02-01 2024-08-08 纽福斯(苏州)生物科技有限公司 质粒包装系统及其应用
CN118633572A (zh) * 2023-03-06 2024-09-13 北京锦篮基因科技有限公司 神经元核内包涵体病小鼠模型构建方法及应用
WO2024223931A1 (en) * 2023-04-28 2024-10-31 AstraZeneca Ireland Limited Manufacturing and use of recombinant self-complementary aav vectors
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025083617A1 (en) * 2023-10-18 2025-04-24 Nanocell Therapeutics Holdings B.V. Methods and compositions for nucleic construct delivery
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025194042A1 (en) 2024-03-14 2025-09-18 Affinia Therapeutics Inc. Plasmid system for production of recombinant adenoassociated virus
EP4628576A1 (en) 2024-04-07 2025-10-08 Ascend Advanced Therapies GmbH Microrna molecules for use in methods for improving recombinant aav production
WO2025238067A1 (en) 2024-05-15 2025-11-20 Ascend Advanced Therapies Gmbh Novel vector system for aav production
WO2026064428A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064444A1 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10044384A1 (de) * 2000-09-08 2002-04-18 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
CA2453405A1 (en) * 2001-07-13 2003-01-23 University Of Iowa Research Foundation Pseudotyped adeno-associated viruses and uses thereof
US20050080027A1 (en) * 2001-11-30 2005-04-14 Markus Horer Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
ES2330826B1 (es) * 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
ES2742180T3 (es) * 2009-03-04 2020-02-13 Deutsches Krebsforsch Proteína activadora del ensamblaje (AAP) y su uso para la fabricación de partículas de parvovirus que consisten esencialmente en VP3
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
HK1202434A1 (en) 2011-11-22 2015-10-02 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP3384034B1 (en) 2015-12-02 2020-07-08 The Board of Trustees of the Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
CN108048483B (zh) * 2018-01-30 2021-02-02 中国疾病预防控制中心病毒病预防控制所 复制型重组腺病毒HAdV-5载体系统及其应用

Similar Documents

Publication Publication Date Title
JP2022530192A5 (enExample)
JP7796702B2 (ja) スペーサーを含む核酸分子およびその使用の方法
JP2022530633A5 (enExample)
JP6174318B2 (ja) アデノ随伴ウイルス構築物を含んでなるコンダクティング気道細胞を標的とするための組成物
JP2022530544A5 (enExample)
Grieger et al. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications
US7220577B2 (en) Modified AAV
US8409842B2 (en) Recombinant adeno-associated virus production
JP2021515548A5 (enExample)
JP2018108113A5 (enExample)
CA2303768A1 (en) Methods and vector constructs useful for production of recombinant aav
CA2349838A1 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US20250236888A1 (en) Recombinant parvoviral vectors and method of making and use thereof
JP2001512674A (ja) 組換えａａｖの生産効率を増強する方法
GB2592752A (en) DNA amplification method
CA3218360A1 (en) System for high-level raav production
CN119487183A (zh) 用于生产重组细小病毒的组合物和方法
JP2025516599A5 (enExample)
JP2024519175A5 (enExample)
CN119842817A (zh) 一种用于生产重组腺相关病毒的新型辅助质粒及其构建方法和应用
US7148341B2 (en) AAV DNA comprising helper virus sequences
CN119569834A (zh) 靶向心肌细胞的aav衣壳蛋白变体及其用途
CN114736928A (zh) 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用
JP2024546578A5 (enExample)
CN117396610A (zh) 使用care元件的dna扩增方法